期刊
FRONTIERS OF MEDICINE
卷 14, 期 2, 页码 210-214出版社
SPRINGER
DOI: 10.1007/s11684-020-0757-x
关键词
novel coronavirus (2019-nCoV); COVID-19; Chinese traditional patent medicine; Shuanghuanglian oral liquid
资金
- Tongji Hospital Clinical Research Flagship Program [2019CR207]
In December 2019, an outbreak of novel Coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to similar to 2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据